Street View: Uncertainty around Hims' GLP-1 business still weighs

Hims & Hers Health's HIMS.N shares slide 7.4% to $14.40 premarket

Telehealth firm on Monday forecast first-quarter revenue below estimates, as it faces regulatory scrutiny over its weight-loss business and invests heavily in international expansion

At least 5 brokerages cut stock's PT

GLP-1 UNCERTAINTY WEIGHS ON FORECAST

BofA Securities ("underperform," PO: $12.5) says "GLP-1 franchise is rapidly eroding and the core business is dealing with competitive pressures that point to revenue for 2026"

Leerink Partners ("market perform," PT: $17.5) says there is "significant uncertainty around the GLP-1 franchise with a number of unresolved matters still swirling" and warns they "can't be confident" in the forecast with "another shoe to drop on the GLP‑1 side"

Citi ("sell/high risk," PT: $13.25) says HIMS' annual forecast leaves key GLP-1 questions unanswered and requires "heavy back-half lift"; warns ongoing GLP‑1 uncertainty makes it hard for co to hit even low end of its revenue forecast

Needham ("hold") says HIMS' FY26 forecast was "disappointing" as weight-loss legal and regulatory uncertainty persists